38. We understand disease and treat it For our thirty-eighth episode, we're exploring a company that has been at the forefront of the fight against cancer for decades. A company that built its empire on a unique, two-pillar strategy that is perfectly suited for the future of healthcare. They don't just want to sell you the cure; they want to sell the test that tells you if the cure will work. It’s a story of visionary acquisitions and world-class science. We are talking about the Swiss giant... Roche. When you hear the name Roche ($RHHBY), you think of a global pharmaceutical powerhouse, a Swiss giant renowned for its leadership in developing cancer treatments. For decades, it has been a defensive cornerstone in portfolios, known for its deep scientific expertise and a vast portfolio of life-saving medicines. But the real story and strategic advantage of Roche lie in its unique dual structure. It is a world leader in not just pharmaceuticals but also in-vitro diagnostics. This powerful combination allows Roche to champion "personalized healthcare"—they can develop a diagnostic test to identify which patients will benefit most from a specific drug, and then provide that targeted therapy. This integrated model creates a formidable competitive moat. However, like all pharma giants, Roche is in a constant race against the patent cliff, with blockbuster drugs facing biosimilar competition. We're analyzing the data to see if Roche's synergistic approach and powerful R&D pipeline are enough to outrun patent expirations and diagnose a healthy future for investors.

📣 New Podcast! "38. We understand disease and treat it" on @Spreaker #biotech #defensive #diagnostics #dividend #drugs #finance #genentech #healthcare #innovation #investing #oncology #patents #personalized #pharma #pipeline #portfolio #rhhby #roche #stock #swiss

News; ( OTC: #RHHBY ) Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

Breaking News: ( OTC: #RHHBY ) FDA Approves Genentech's Lunsumio VELO(TM) for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

#PFE #RHHBY #VKTX #25bef349-8051-42bc-8969-dbf4ee7c35c9 #investing #Health #Care

Origin | Interest | Match

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology Roche (ROG) announced on October 13, 2025 that the FDA cleared its Elecsys pTau181 blood test as the only blood-based biomarker test indicated for use in primary care to help rule out Alzheimer's-related amyloid pathology. The test is for patients aged 55 and older, was developed with Eli Lilly, and showed a 97.9% negative predictive value in a multicenter study of 312 participants reflective of a primary-care population. With > 4,500 Roche instruments already in U.S. labs and recent CE Mark/IVDR certification, Roche says the test can broaden access, improve referrals, and reduce more invasive confirmatory testing such as PET and CSF.

#ROG #RHHBY Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

www.stocktitan.net/news/ROG/roche-s-elecsys...

JUST IN: ( OTC: #RHHBY ) Positive Phase III Results Show Genentech's Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

Just In: ( OTC: #RHHBY ) New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension Genentech, a member of the Roche Group and Alnylam today announced the decision to initiate a Phase III cardiovascular outcomes trial to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA...

#RHHBY #ALNY Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

www.stocktitan.net/news/RHHBY/genentech-and...

#VKTX #MRK #NVO #LLY #PFE #BMY #RHHBY #HIMS #4e306a68-5e2b-47dc-8f72-b5ce285a1e17 #investing

Origin | Interest | Match

Just In: ( OTC: #RHHBY ) Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

Breaking News: ( OTC: #RHHBY ) New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

www.fool.com/investing/2025/05/13/why...

#NVO #RHHBY #LLY #VKTX […]

[Original post on fool.com]

🏥 Roche (RHHBY) to invest $50B in U.S. over 5 years, creating 12,000+ jobs. Focus on manufacturing expansion and AI-driven health solutions. Full analysis: buff.ly/8ohRaPk #Roche #RHHBY #Pharmaceuticals #Investment #Innovation

www.fool.com/investing/2025/04/09/roc...

#AZN #RHHBY #LLY […]

[Original post on fool.com]

Original post on seekingalpha.com

Trump’s medical tariffs could significantly hurt these European healthcare firms

seekingalpha.com/news/4426700-trumps-medi...

#mdt #nvs #prgo #bayry #rhhby #fms #jazz #ste #amrn […]

Breaking News: ( OTC: #RHHBY ) New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis

Roche Secures FDA Clearance for Revolutionary B-Cell Lymphoma Test, First of Its Kind Roche's VENTANA Dual ISH test receives FDA approval, offering groundbreaking single-slide diagnosis for all B-cell lymphoma subtypes, streamlining cancer detection and treatment.

#RHHBY #ROG Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma

www.stocktitan.net/news/RHHBY/roche-receive...

#PFE #RHHBY #MRNA #NVAX all up today.. 👀 on #H5N1

#CCR8 companies presenting at #JPM2025.... #BMY #ZLAB #CHRS #BGNE #AMGN #BAYN.DE #ABBV #RHHBY #GILD

The risk of a bird flu pandemic is rising Human cases in the US are on the rise and the virus is turning up in cows and dairy products. Luckily, we have some vaccines ready to go if needed.

PSA #RHHBY holds worldwide rights to Xofluza, excluding Japan and Taiwan.

"Virologists have been especially worried about the virus making its way into pigs, because these animals are notorious viral incubators." #H5N1 #Birdflu
www.technologyreview.com/2024/11/29/1...

#RHHBY #ROG Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

www.stocktitan.net/news/RHHBY/roche-receive...

Breaking News: ( OTC: #RHHBY ) Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

#StockMarket #News

JUST IN: ( OTC: #RHHBY ) Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

#StockMarket #News

Just In: ( OTC: #RHHBY ) Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

#StockMarket #News